MyoTherix Overview
- Founded
- 2013
- Status
- Private
- Latest Deal Type
- Early Stage VC
- Latest Deal Amount
- $8.43M
- Investors
- 1
MyoTherix General Information
Description
Developer of innovative therapeutics intended to be used for the treatment of muscle disorders. The company utilizes an innovative and novel approach to target both cardiac and skeletal muscle weakness, enabling patients to avail disease-modifying drugs and therapies and stay fit and healthy.
Contact Information
Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Delivery
Other Industries
Discovery Tools (Healthcare)
Biotechnology
Primary Office
- 1900 Powell Street
- 6th Floor
- Emeryville, CA 94608
- United States
+1 (857) 000-0000
MyoTherix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Early Stage VC | 27-Feb-2017 | $8.43M | 00.00 | Completed | Startup | |
| 1. Early Stage VC (Series A) | 08-Jul-2015 | 000 | 000 | 000 | Completed | Startup |
MyoTherix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A | 0,000,000 | 00.000000 | 00 | 00 | 00 | 00 | 00 | 00.00 |
MyoTherix Executive Team (5)
MyoTherix Board Members (5)
| Name | Representing | Role | Since |
|---|---|---|---|
| Babar Ghias | Self | Board Member | 000 0000 |
| John Kincaid | MyoTherix | Co-Founder & Board Member | 000 0000 |
| Mark De Souza Ph.D | Self | Co-Founder, Chief Operating Officer & Chairman | 000 0000 |
| Michael Kelly Ph.D | MyoTherix | Co-Founder, Chief Executive Officer, President & Board Member | 000 0000 |
MyoTherix Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| CureDuchenne Ventures | Corporate Venture Capital | Minority | 000 0000 | 000000 0 |